About Deliberate.ai
Deliberate AI enhances mental healthcare and clinical trials through data-driven diagnostics and monitoring. Their products help clinicians manage patient data effectively, improving the accuracy of clinical endpoints and the detection of treatment effects. The company serves mental healthcare providers with tools for measurement-based care and collaborates with researchers to optimize clinical trials, making them more efficient. Deliberate AI aims to improve data management in healthcare, ultimately accelerating the development of new treatments.
New York City, New YorkHeadquarters
2020Year Founded
$29.2KTotal Funding
GRANTCompany Stage
Data & Analytics, Biotechnology, HealthcareIndustries
1-10Employees
Risks
Increased competition from PharmStars cohort could dilute market share.
Stringent FDA requirements may delay AI-COA™ tool deployment.
Data privacy concerns may impact user trust in AI-driven mental health assessments.
Differentiation
Deliberate AI's AI-COA™ is the first AI/ML tool in FDA's ISTAND program.
The company focuses on precision therapy enablement and ambient clinical intelligence.
Deliberate AI enhances endpoint accuracy and reliability in mental health clinical trials.
Upsides
Inclusion in FDA's ISTAND program boosts credibility and potential for faster approvals.
Growing market acceptance of AI in mental health diagnostics indicates partnership opportunities.
AI-driven remote patient monitoring is expanding, complementing Deliberate AI's capabilities.
Funding
Total raised$29.2 K
StageGRANT
GRANT
1/31/2020N/A